# reload+after+2024-01-23 20:46:28.549359
address1§240 East Grand Avenue
address2§2nd Floor
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 388 5600
website§https://www.oricpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
fullTimeEmployees§93
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Richard A. Heyman Ph.D.', 'age': 66, 'title': 'Co-Founder, Independent Chairman & Member of Scientific Advisory Board', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 93000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jacob M. Chacko M.B.A., M.D.', 'age': 44, 'title': 'President, CEO & Director', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 921321, 'exercisedValue': 0, 'unexercisedValue': 3648645}, {'maxAge': 1, 'name': 'Mr. Dominic G. Piscitelli CPA, M.B.A.', 'age': 48, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 636913, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pratik S. Multani M.D., M.S.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 686881, 'exercisedValue': 0, 'unexercisedValue': 992063}, {'maxAge': 1, 'name': 'Dr. Charles L. Sawyers B.A., M.D., Ph.D.', 'age': 64, 'title': 'Co-Founder & Member of Scientific Advisory Board', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Scott W. Lowe Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lori Sickels Friedman Ph.D.', 'age': 59, 'title': 'Chief Scientific Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christian V. Kuhlen Esq., J.D., M.D.', 'age': 50, 'title': 'General Counsel', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel  Iazzetti', 'title': 'VP & Head of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edna  Chow Maneval', 'age': 63, 'title': 'Senior Vice President of Clinical Development', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§4
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.982
currency§USD
dateShortInterest§1702598400
forwardEps§-2.15
exchange§NMS
quoteType§EQUITY
shortName§Oric Pharmaceuticals, Inc.
longName§ORIC Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1587735000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§dc096b5b-6f44-3289-9c72-d0a4b5607b05
gmtOffSetMilliseconds§-18000000
targetHighPrice§27.0
targetLowPrice§12.0
targetMeanPrice§16.25
targetMedianPrice§15.0
recommendationMean§1.2
recommendationKey§strong_buy
numberOfAnalystOpinions§8
quickRatio§11.998
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
